Detection of mutations in EGFR in circulating lung-cancer cells.

By S. Maheswaran, L. Sequist, S. Nagrath, L. Ulkus, Brian W. Brannigan, Chey Collura, Elizabeth J. Inserra, Sven Diederichs, A. Iafrate, D. Bell and 8 more. New England Journal of Medicine, 2008

1,564 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/7648c4036fc78f6f3bfb927a0c0e07e028127626

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Matthew Meyerson
2. Gad Getz
3. D. Louis
4. K. Pantel
5. C. Alix‐Panabières

In Oncology

1. J. Engelman
2. P. Jänne
3. William Pao
4. Jie Yang
5. Gad Getz
6. D. Louis
7. J. Chmielecki
8. K. Pantel

In Pulmonary and Respiratory Medicine

1. J. Engelman
2. P. Jänne
3. William Pao
4. L. Sequist
5. J. Chmielecki
6. K. Pantel
7. Carlos L. Arteaga
8. Jin-Yuan Shih

Citations in the corpus

• Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells (2013, methodology): “Once detected, enumeration and molecular characterization of CTCs have been applied to prognostic classifications of breast, prostate, and colon cancers (3), and to predictive markers of targeted drug therapy in lung cancer (4).”
• RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics (2015, neutral): “…evaluated as liquid biopsies, including plasma DNA (Bettegowda et al., 2014; Chan et al., 2013; Diehl et al., 2008; Murtaza et al., 2013; Newman et al., 2014; Thierry et al., 2014) and circulating tumor cells (Bidard et al., 2014; Dawson et al., 2013; Maheswaran et al., 2008; Rack et al., 2014).”
• Circulating tumor cells: approaches to isolation and characterization (2011, positive): “In our initial studies, EGFR mutations identified in lung CTCs were concordant with the mutations known to be present in the primary tumor in 12/13 cases (Maheswaran et al., 2008).”
• Pre-existence and clonal selection of MET amplification in EGFR mutant NSCLC (2010, methodology): “low levels in patients with EGFR-mutant NSCLC prior to gefitinib or erlotinib treatment (Maheswaran et al., 2008).”
• Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers (2012, background): “On the basis of our understanding of EGFR TKI resistance, certain resistance mechanisms may preexist in crizotinibnaïve patients (18, 43, 44).”
• Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA (2012, background): “This could also be applied to screen for rare mutations in a variety of heterogeneous sample types such as low-cellularity tumor specimens, cytological samples, or circulating tumor cells (16).”
• Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. (2013, background): “T790M mutations may already be present in EGFR TKI treatment– naive patients,(26,27) and the presence of a detectable de novo T790M mutation predicts for shorter PFS with EGFR TKIs.(26,28,29) Afatinib had in vitro activity against the T790M variant(10) and improved PFS compared with placebo in a ran”
• Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors (2009, neutral): “A molecular analysis of circulating cells may provide an alternative approach for monitoring tumor mutations (Maheswaran et al., 2008).”